EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 20:58  – Posting: # 20959
Views: 2,626

Dear Osama,

» I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
20,789 posts in 4,353 threads, 1,445 registered users;
online 14 (3 registered, 11 guests [including 2 identified bots]).
Forum time: 16:55 CEST (Europe/Vienna)

Art is “I”; science is “we”.    Claude Bernard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5